Publications

  1. Hankinson, E., Reiss, S., Ward, P. J., Jarrett, B. A., Mbah, O. M., Yerram, P., … (2025). Assessment of racial/ethnic inequities in uptake of PSMA-PET imaging among patients with metastatic prostate cancer in the United States. Journal of Clinical Oncology, 43(16_suppl), e13739-e13739.
  2. Waterhouse, D. M., LeBlanc, T. W., Heiland, K., Anderson, K., Beck, Z. T., Ward, P. J., … (2025). A digital intervention to enhance engagement with oral oncolytic treatments and assess patient experiences with novel therapies. Journal of Clinical Oncology, 43(16_suppl), 11056-11056.
  3. Wang, B., Evangelist, M. C., Butrynski, J. E., Paschold, J. C., Ward, P. J., Hakimian, D., … (2025). Testing and treatment patterns in KRAS mutant mNSCLC: Results from the MYLUNG Consortium. Journal of Clinical Oncology, 43(16_suppl), e20639-e20639.
  4. Rodriguez, C. P., Lee, S., Watson, G., Gillespie-Twardy, A. L., Laux, D. E., Ward, P. J., … (2025). Phase 2 open-label study of brentuximab vedotin (BV)+ pembrolizumab (pembro) in patients (pts) with treatment (tx)-naive metastatic head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology, 43(16_suppl), 6015-6015.
  5. Fidyk, E., Ward, P. J., Estevez, M., Krismer, K., Ritten, J. J., Marinescu, A., … (2025). Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC). Journal of Clinical Oncology, 43(16_suppl), 555-555.
  6. Coombes, R. C., Howell, S., Lord, S. R., Kenny, L., Mansi, J., Mitri, Z., … (2025). Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications, 16(1), 2242.
  7. Lee, S. M., Hamid, O., Jotte, R., Zakharia, Y., Medina, T., Gillespie-Twardy, A., … (2025). Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. Clinical Cancer Research, OF1-OF12.
  8. Mendenhall, M., Drosick, D. R., Ward, P. J., Burdette, C., Davies, D., Mink, H., … (2024). Utilization of Lean Six Sigma and the DMAIC process on oral treatment regimen entry and consent to improve patient care and mitigate practice risk. JCO Oncology Practice, 20(10_suppl), 281-281.
  9. Mendenhall, M., Drosick, D. R., Ward, P. J., Davies, D., Sheldrick, A., Brown, A., … (2024). Quality improvement scorecards driving innovation and best practice in a large community oncology practice. JCO Oncology Practice, 20(10_suppl), 417-417.
  10. Armstrong, A. J., Appleman, L. J., Danila, D. C., Lin, C. C., Lee, J. L., Matsubara, N., … (2024). 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig. Annals of Oncology.
  11. Kelly, W. K., Appleman, L. J., Lin, C. C., Armstrong, A. J., Fischer, S. C., Pook, D. W., … (2024). 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+ 1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion…. Annals of Oncology.
  12. Evangelist, M. C., Butrynski, J. E., Paschold, J. C., Ward, P. J., Waterhouse, D. M., … (2024). Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium. Journal of Clinical Oncology, 42(16_suppl), 8047-8047.
  13. Zakharia, Y., Lee, S., Jotte, R. M., Gillespie-Twardy, A. L., Mehmi, I., Chandra, S., … (2024). Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma…. Journal of Clinical Oncology, 42(16_suppl), 2617-2617.
  14. Mendenhall, M., Waterhouse, D., Drosick, R., Ward, P., Davies, D. (2024). A Model for Achieving Comprehensive Biomarker Testing in Non–Small Cell Lung Cancer. Oncology Issues, 39(1), 20-29.
  15. Mendenhall, M. A., Guinigundo, A., Davies, D., Ward, P., Drosick, D. R., … (2024). Integration of genetic testing and counseling in patients with breast cancer in a large, multisite community-based practice. JCO Oncology Practice, 20(2), 262-267.
  16. Kelly, W. K., Danila, D. C., Lin, C. C., Lee, J. L., Matsubara, N., Ward, P. J., … (2024). Xaluritamig, a STEAP1× CD3 XmAb 2+ 1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study. Cancer Discovery, 14(1), 76-89.
  17. Zalcman, G., AM, C. D., Syrigos, K., Livi, L., Paulus, A., Kim, S. W., … (2024). Efficacité intracrânienne du sotorasib versus docétaxel dans le cancer bronchique non à petites cellules (CBNPC) métastatique muté KRAS G12C données utiles à la pratique issues…. Revue des Maladies Respiratoires Actualités, 16(1), 265.
  18. Borghaei, H., De Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W., … (2024). SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Annals of Oncology, 35(1), 66-76.
  19. Lee, S., Jotte, R. M., Gillespie-Twardy, A., Mehmi, I., Chandra, S., Zakharia, Y., … (2023). 699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after…. Journal for ImmunoTherapy of Cancer, 11(Suppl 1).
  20. Waterhouse, D. M., Ward, P., Drosick, D. R., Burdette, C., Davies, D., … (2023). Sustainable Integration of US Food and Drug Administration–Approved Biosimilars: Pharmacy-Versus Physician-Driven Change. JCO Oncology Practice, 19(11), 1053-1057.